DAX ®12.633,60-0,17%TecDAX ®2.778,43-0,81%Dow Jones26.770,20-0,95%NASDAQ 1007.868,49-0,93%
finanztreff.de

DGAP-Adhoc: Biofrontera AG: ???????Biofrontera reports preliminary unaudited sales revenue for the first nine months of 2019

| Quelle: Dow Jones Newsw... | Lesedauer etwa 3 min. | Text vorlesen Stop Pause Fortsetzen


DGAP-Ad-hoc: Biofrontera AG / Key word(s): Quarter Results/9 Month figures
Biofrontera AG: ???????Biofrontera reports preliminary unaudited sales
revenue for the first nine months of 2019

10-Oct-2019 / 11:15 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

*Biofrontera reports preliminary unaudited sales revenue for the first nine
months of 2019*

Leverkusen, Germany, 10.10.2019 - Biofrontera AG (NASDAQ: BFRA; Frankfurt
Stock Exchange: B8F) (the "Company" or the "Biofrontera-group"), an
international biopharmaceutical company, today reports preliminary unaudited
revenue for the third quarter of fiscal year 2019.

The Biofrontera-Group generated sales of approximately EUR 18.9 to 19.2
million in the period from January 1st to September 30th, 2019. This
corresponds to a sales growth of about 30% compared to the same period last
year (EUR 14.6 million).
Preliminary unaudited nine-month sales of Ameluz(R) in the U.S. were between
EUR 12.8 and 13.0 million, compared to EUR 10.2 million (approximately +25%)
in the same period in 2018. Product sales of Xepi(TM) and AKTIPAK(R)
contributed about EUR 0.7 million to sales since the acquisition of Cutanea
Life Sciences, Inc. in late March 2019. Revenue in Germany increased by
about 60% to EUR 3.1 to 3.3 million in the reporting period compared to EUR
2.1 million in the first nine months of 2018. In the remainder of Europe
product sales were between 1.7 to 1.9 million, compared to 2.1 million
(approximately -15%) in the prior-year period.
While growth in Germany continued to be very dynamic, this year's sales in
the U.S. in the third quarter declined by about 15% from EUR 3.8 million in
2018. This is due to positive one-off effects in September 2018 before a
price increase that took effect on October 1, 2018. The company continues to
see the fourth quarter as the key revenue driver for its growing business in
all markets.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611

Contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
E-mail: ir@biofrontera.com

10-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: ir@biofrontera.com
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard);
Regulated Unofficial Market in Berlin, Hamburg, Munich,
Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 888181

End of Announcement DGAP News Service

888181 10-Oct-2019 CET/CEST



(END) Dow Jones Newswires

October 10, 2019 05:15 ET ( 09:15 GMT)
Werbung

Das könnte Sie auch interessieren

News-Suche

Suchbegriff:
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 43 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen